7-Chloro-3-methyl-2H-benzo[1,2,4]thiadiazine 1,1-dioxide

ID: ALA181

Max Phase: Approved

First Approval: 1973

Molecular Formula: C8H7ClN2O2S

Molecular Weight: 230.68

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Diazoxide | Diazoxidum | Eudemine injection | Hypertonalum | NSC-64198 | NSC-76130 | SCH 6783 | SCH-6783 | SRG 95213 | SRG-95213

Synonyms from Alternative Forms(1): Diazoxide choline

Trade Names(6): Diazoxide | Eudemine | Eudimine | Hyperstat | Mutabase | Proglycem

Canonical SMILES:  CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1

Standard InChI:  InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)

Standard InChI Key:  GDLBFKVLRPITMI-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 14 15  0  0  0  0  0  0  0  0999 V2000
    5.7417   -5.1875    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    6.3542   -4.8375    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.1292   -4.8375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7417   -3.8000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.3542   -4.1417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1292   -4.1417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3792   -5.8542    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.1292   -5.8542    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.5167   -5.1875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5167   -3.8000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9042   -4.8375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9042   -4.1417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2917   -5.1875    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    6.9667   -3.8000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  1  1  0
  4  6  1  0
  5  2  1  0
  6  3  1  0
  7  1  2  0
  8  1  2  0
  9  3  2  0
 10  6  2  0
 11  9  1  0
 12 11  2  0
 13 11  1  0
 14  5  1  0
  4  5  2  0
 12 10  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA181

   DIAZOXIDE

2. Alternative Forms:

   

   ALA181

   DIAZOXIDE CHOLINE

Molecule Features

Natural Product: Yes

Oral: Yes

Chemical Probe: No

Parenteral: Yes

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: Yes

Availability: Yes

Prodrug: No

Calculated Properties

Molecular Weight: 230.68

Molecular Weight (Monoisotopic): 229.9917

AlogP: 1.68

#Rotatable Bonds: ┄

Polar Surface Area: 58.53

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 6.66

CX Basic pKa: 0.92

CX LogP: 1.13

CX LogD: 0.53

Aromatic Rings: 1

Heavy Atoms: 14

QED Weighted: 0.74

Np Likeness Score: -1.38

References

1. Pirotte B, Ouedraogo R, de Tullio P, Khelili S, Somers F, Boverie S, Dupont L, Fontaine J, Damas J, Lebrun P..  (2000)  3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.,  43  (8): [PMID:10780901] [10.1021/jm991069o]

2. Coghlan MJ, Carroll WA, Gopalakrishnan M..  (2001)  Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.,  44  (11): [PMID:11356099] [10.1021/jm000484+]

3. Tagmose TM, Mogensen JP, Agerholm PC, Arkhammar PO, Wahl P, Worsaae A, Hansen JB..  (2001)  Phenylcyanoguanidines as inhibitors of glucose-induced insulin secretion from beta cells.,  11  (13): [PMID:11425552] [10.1016/s0960-894x(01)00297-9]

4. Manley PW, Quast U, Andres H, Bray K..  (1993)  Synthesis of and radioligand binding studies with a tritiated pinacidil analogue: receptor interactions of structurally different classes of potassium channel openers and blockers.,  36  (14): [PMID:8336339] [10.1021/jm00066a009]

5. Yoshida F, Topliss JG..  (2000)  QSAR model for drug human oral bioavailability.,  43  (13): [PMID:10891117] [10.1021/jm0000564]

6. Somers F, Ouedraogo R, Antoine MH, de Tullio P, Becker B, Fontaine J, Damas J, Dupont L, Rigo B, Delarge J, Lebrun P, Pirotte B..  (2001)  Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.,  44  (16): [PMID:11472211] [10.1021/jm0004648]

7. Pirotte B, Podona T, Diouf O, de Tullio P, Lebrun P, Dupont L, Somers F, Delarge J, Morain P, Lestage P, Lepagnol J, Spedding M..  (1998)  4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors: design, synthesis, pharmacology, and structure-activity relationships.,  41  (16): [PMID:9685234] [10.1021/jm970694v]

8. Peat AJ, Townsend C, Worley JF, Allen SH, Garrido D, Mertz RJ, Pfohl JL, Terry CM, Truax JF, Veasey RL, Thomson SA..  (2002)  Synthesis and evaluation of 7-substituted-3-cyclobutylamino-4H-1,2,4-benzothiadiazine-1,1-dioxide derivatives as K(ATP) channel agonists.,  12  (20): [PMID:12270187] [10.1016/s0960-894x(02)00617-0]

9. Tagmose TM, Schou SC, Mogensen JP, Nielsen FE, Arkhammar PO, Wahl P, Hansen BS, Worsaae A, Boonen HC, Antoine MH, Lebrun P, Hansen JB..  (2004)  Arylcyanoguanidines as activators of Kir6.2/SUR1K ATP channels and inhibitors of insulin release.,  47  (12): [PMID:15163199] [10.1021/jm031018y]

10. Pirotte B, de Tullio P, Lebrun P, Antoine MH, Fontaine J, Masereel B, Schynts M, Dupont L, Herchuelz A, Delarge J..  (1993)  3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?,  36  (21): [PMID:8230110] [10.1021/jm00073a025]

11. de Tullio P, Becker B, Boverie S, Dabrowski M, Wahl P, Antoine MH, Somers F, Sebille S, Ouedraogo R, Hansen JB, Lebrun P, Pirotte B..  (2003)  Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.,  46  (15): [PMID:12852765] [10.1021/jm021117w]

12. McNeal ET, Lewandowski GA, Daly JW, Creveling CR..  (1985)  [3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.,  28  (3): [PMID:2579237] [10.1021/jm00381a019]

13. Nielsen FE, Bodvarsdottir TB, Worsaae A, MacKay P, Stidsen CE, Boonen HC, Pridal L, Arkhammar PO, Wahl P, Ynddal L, Junager F, Dragsted N, Tagmose TM, Mogensen JP, Koch A, Treppendahl SP, Hansen JB..  (2002)  6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.,  45  (19): [PMID:12213059] [10.1021/jm0208121]

14. Peat AJ, Townsend C, Craig McKay M, Garrido D, Terry CM, Wilson JL, Thomson SA..  (2004)  3-trifluoromethyl-4-nitro-5-arylpyrazoles are novel K(ATP) channel agonists.,  14  (3): [PMID:14741296] [10.1016/j.bmcl.2003.10.066]

15. de Tullio P, Pirotte B, Lebrun P, Fontaine J, Dupont L, Antoine MH, Ouedraogo R, Khelili S, Maggetto C, Masereel B, Diouf O, Podona T, Delarge J..  (1996)  3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships.,  39  (4): [PMID:8632417] [10.1021/jm9500582]

16. Sebille S, de Tullio P, Becker B, Antoine MH, Boverie S, Pirotte B, Lebrun P..  (2005)  4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.,  48  (2): [PMID:15658874] [10.1021/jm040789e]

17. Nielsen FE, Jacobsen P, Worsaae A, Arkhammar PO, Wahl P, Bondo Hansen J..  (2004)  2-(4-Methoxyphenoxy)-5-nitro-N-(4-sulfamoylphenyl)benzamide activates Kir6.2/SUR1 K(ATP) channels.,  14  (23): [PMID:15501029] [10.1016/j.bmcl.2004.09.057]

18. de Tullio P, Boverie S, Becker B, Antoine MH, Nguyen QA, Francotte P, Counerotte S, Sebille S, Pirotte B, Lebrun P..  (2005)  3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: effect of 6,7-disubstitution on potency and tissue selectivity.,  48  (15): [PMID:16033278] [10.1021/jm0580050]

19. Boverie S, Antoine MH, Somers F, Becker B, Sebille S, Ouedraogo R, Counerotte S, Pirotte B, Lebrun P, de Tullio P..  (2005)  Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.,  48  (10): [PMID:15887958] [10.1021/jm0311339]

20. Nielsen FE, Ebdrup S, Jensen AF, Ynddal L, Bodvarsdottir TB, Stidsen C, Worsaae A, Boonen HC, Arkhammar PO, Fremming T, Wahl P, Kornø HT, Hansen JB..  (2006)  New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.,  49  (14): [PMID:16821773] [10.1021/jm060042j]

21. Breschi MC, Calderone V, Martelli A, Minutolo F, Rapposelli S, Testai L, Tonelli F, Balsamo A..  (2006)  New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.,  49  (26): [PMID:17181142] [10.1021/jm061228l]

22. Carosati E, Mannhold R, Wahl P, Hansen JB, Fremming T, Zamora I, Cianchetta G, Baroni M..  (2007)  Virtual screening for novel openers of pancreatic K(ATP) channels.,  50  (9): [PMID:17425298] [10.1021/jm061440p]

23. Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F..  (2008)  Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.,  51  (21): [PMID:18834112] [10.1021/jm800656v]

24. Rapposelli S, Calderone V, Cirilli R, Digiacomo M, Faggi C, La Torre F, Manganaro M, Martelli A, Testai L..  (2009)  Enantioselectivity in cardioprotection induced by (S)- (-)-2,2-dimethyl-N-(4'-acetamido-benzyl)-4-spiromorpholone-chromane.,  52  (5): [PMID:19215088] [10.1021/jm801459f]

25. Sebille S, de Tullio P, Florence X, Becker B, Antoine MH, Michaux C, Wouters J, Pirotte B, Lebrun P..  (2008)  New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.,  16  (10): [PMID:18406154] [10.1016/j.bmc.2008.03.065]

26. Khelili S, Florence X, Bouhadja M, Abdelaziz S, Mechouch N, Mohamed Y, de Tullio P, Lebrun P, Pirotte B..  (2008)  Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.,  16  (11): [PMID:18479927] [10.1016/j.bmc.2008.04.043]

27. Breschi MC, Calderone V, Digiacomo M, Manganaro M, Martelli A, Minutolo F, Rapposelli S, Testai L, Tonelli F, Balsamo A..  (2008)  Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.,  51  (21): [PMID:18925735] [10.1021/jm800956g]

28. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A..  (2009)  Physicochemical determinants of human renal clearance.,  52  (15): [PMID:19445515] [10.1021/jm900403j]

29. Coi A, Bianucci AM, Calderone V, Testai L, Digiacomo M, Rapposelli S, Balsamo A..  (2009)  Predictive models, based on classification algorithms, for compounds potentially active as mitochondrial ATP-sensitive potassium channel openers.,  17  (15): [PMID:19595602] [10.1016/j.bmc.2009.06.028]

30. Pirotte B, de Tullio P, Nguyen QA, Somers F, Fraikin P, Florence X, Wahl P, Hansen JB, Lebrun P..  (2010)  Chloro-substituted 3-alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel activators: impact of the position of the chlorine atom on the aromatic ring on activity and tissue selectivity.,  53  (1): [PMID:19919106] [10.1021/jm9010093]

31. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD..  (2010)  Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,  53  (3): [PMID:20070106] [10.1021/jm901371v]

32. Florence X, Sebille S, Tullio Pd, Lebrun P, Pirotte B..  (2009)  New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.,  17  (22): [PMID:19822435] [10.1016/j.bmc.2009.09.041]

33. Prado-Prado FJ, García-Mera X, González-Díaz H..  (2010)  Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.,  18  (6): [PMID:20185316] [10.1016/j.bmc.2010.01.068]

34. Gozalbes R, Pineda-Lucena A..  (2010)  QSAR-based solubility model for drug-like compounds.,  18  (19): [PMID:20810286] [10.1016/j.bmc.2010.08.003]

35. Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB..  (2007)  Chemical genetics reveals a complex functional ground state of neural stem cells.,  3  (5): [PMID:17417631] [10.1038/nchembio873]

36. PubChem BioAssay data set, 

37. PubChem BioAssay data set, 

38. PubChem BioAssay data set, 

39. PubChem BioAssay data set, 

40. PubChem BioAssay data set, 

41. PubChem BioAssay data set, 

42. Obach RS, Lombardo F, Waters NJ..  (2008)  Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.,  36  (7): [PMID:18426954] [10.1124/dmd.108.020479]

43. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A..  (2010)  Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.,  23  (1): [PMID:20014752] [10.1021/tx900326k]

44. Unpublished dataset, 

45. Rapposelli S, Breschi MC, Calderone V, Digiacomo M, Martelli A, Testai L, Vanni M, Balsamo A..  (2011)  Synthesis and biological evaluation of 5-membered spiro heterocycle-benzopyran derivatives against myocardial ischemia.,  46  (3): [PMID:21288603] [10.1016/j.ejmech.2011.01.003]

46. Pirotte B, de Tullio P, Boverie S, Michaux C, Lebrun P..  (2011)  Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.,  54  (9): [PMID:21428460] [10.1021/jm200100c]

47. PubChem BioAssay data set, 

48. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, 

49. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W..  (2011)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).,  7  (12): [PMID:22194678] [10.1371/journal.pcbi.1002310]

50. Khelili S, Kihal N, Yekhlef M, de Tullio P, Lebrun P, Pirotte B..  (2012)  Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells.,  54  [PMID:22647221] [10.1016/j.ejmech.2012.05.011]

51. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

52. Pirotte B, de Tullio P, Florence X, Goffin E, Somers F, Boverie S, Lebrun P..  (2013)  1,4,2-Benzo/pyridodithiazine 1,1-dioxides structurally related to the ATP-sensitive potassium channel openers 1,2,4-Benzo/pyridothiadiazine 1,1-dioxides exert a myorelaxant activity linked to a distinct mechanism of action.,  56  (8): [PMID:23517501] [10.1021/jm301743b]

53. PubChem BioAssay data set, 

54. PubChem BioAssay data set, 

55. Martelli A, Manfroni G, Sabbatini P, Barreca ML, Testai L, Novelli M, Sabatini S, Massari S, Tabarrini O, Masiello P, Calderone V, Cecchetti V..  (2013)  1,4-Benzothiazine ATP-sensitive potassium channel openers: modifications at the C-2 and C-6 positions.,  56  (11): [PMID:23662847] [10.1021/jm400435a]

56. Constant-Urban C, Charif M, Goffin E, Van Heugen JC, Elmoualij B, Chiap P, Mouithys-Mickalad A, Serteyn D, Lebrun P, Pirotte B, De Tullio P..  (2013)  Triphenylphosphonium salts of 1,2,4-benzothiadiazine 1,1-dioxides related to diazoxide targeting mitochondrial ATP-sensitive potassium channels.,  23  (21): [PMID:24055044] [10.1016/j.bmcl.2013.08.091]

57. De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP..  (2013)  Structure-based identification of OATP1B1/3 inhibitors.,  83  (6): [PMID:23571415] [10.1124/mol.112.084152]

58. Giannetti AM, Zheng X, Skelton NJ, Wang W, Bravo BJ, Bair KW, Baumeister T, Cheng E, Crocker L, Feng Y, Gunzner-Toste J, Ho YC, Hua R, Liederer BM, Liu Y, Ma X, O'Brien T, Oeh J, Sampath D, Shen Y, Wang C, Wang L, Wu H, Xiao Y, Yuen PW, Zak M, Zhao G, Zhao Q, Dragovich PS..  (2014)  Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,  57  (3): [PMID:24405419] [10.1021/jm4015108]

59. PubChem BioAssay data set, 

60. Florence X, Desvaux V, Goffin E, de Tullio P, Pirotte B, Lebrun P..  (2014)  Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?,  80  [PMID:24763361] [10.1016/j.ejmech.2014.04.024]

61. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

62. Bouider N, Fhayli W, Ghandour Z, Boyer M, Harrouche K, Florence X, Pirotte B, Lebrun P, Faury G, Khelili S..  (2015)  Design and synthesis of new potassium channel activators derived from the ring opening of diazoxide: study of their vasodilatory effect, stimulation of elastin synthesis and inhibitory effect on insulin release.,  23  (8): [PMID:25773016] [10.1016/j.bmc.2015.02.043]

63. Harrouche K, Renard JF, Bouider N, de Tullio P, Goffin E, Lebrun P, Faury G, Pirotte B, Khelili S..  (2016)  Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.,  115  [PMID:27031211] [10.1016/j.ejmech.2016.03.028]

64. WHO Anatomical Therapeutic Chemical Classification, 

65. British National Formulary (72nd edition), 

66. Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR..  (2017)  A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.,  27  (3): [PMID:28049589] [10.1016/j.bmcl.2016.12.056]

67. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK..  (2010)  Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.,  118  (2): [PMID:20829430] [10.1093/toxsci/kfq269]

68. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T..  (2012)  Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.,  40  (12): [PMID:22961681] [10.1124/dmd.112.047068]

69. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK..  (2013)  A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,  136  (1): [PMID:23956101] [10.1093/toxsci/kft176]

70. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W..  (2016)  DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.,  21  (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015]

71. Bouhedja M, Peres B, Fhayli W, Ghandour Z, Boumendjel A, Faury G, Khelili S..  (2018)  Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis.,  144  [PMID:29291445] [10.1016/j.ejmech.2017.12.071]

72. Unpublished dataset, 

73. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard.  (2020)  In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication,  [10.1101/2020.04.03.023846]

74. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson.  (2020)  Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,  [10.1101/2020.04.21.054387]

75. Méndez M, Matter H, Defossa E, Kurz M, Lebreton S, Li Z, Lohmann M, Löhn M, Mors H, Podeschwa M, Rackelmann N, Riedel J, Safar P, Thorpe DS, Schäfer M, Weitz D, Breitschopf K..  (2020)  Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).,  63  (5): [PMID:31596080] [10.1021/acs.jmedchem.9b01071]

76. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

77. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

78. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of NIH (USA) - Clinical Collection,  [10.6019/CHEMBL4513141]

79. Ellen Van Damme.  (2021)  Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity,  [10.6019/CHEMBL4651402]

80. Pirotte B,Florence X,Goffin E,Medeiros MB,de Tullio P,Lebrun P.  (2016)  4-Phenylureido/thioureido-substituted 2,2-dimethylchroman analogs of cromakalim bearing a bulky 'carbamate' moiety at the 6-position as potent inhibitors of glucose-sensitive insulin secretion.,  121  [PMID:27267004] [10.1016/j.ejmech.2016.05.042]

81. Huwaimel BI, Jonnalagadda S, Jonnalagadda S, Zahra FT, Nocentini A, Supuran CT, Mikelis CM, Trippier PC..  (2022)  Chlorinated benzothiadiazines inhibit angiogenesis through suppression of VEGFR2 phosphorylation.,  67  [PMID:35635929] [10.1016/j.bmc.2022.116805]

82. Han Y, Cheng Y, Tian LW..  (2023)  Semisynthesis of 22,25-Epoxylanostane Triterpenoids: Structure Revision and Protective Effects against Oxygen-Glucose Deprivation/Reoxygenation Injury in H9c2 Cells.,  86  (2.0): [PMID:36748235] [10.1021/acs.jnatprod.2c01029]

83. Dodd CJ, Chronister KS, Rathnayake U, Parr LC, Li K, Chang S, Mi D, Days EL, Bauer JA, Cho HP, Boutaud O, Denton JS, Lindsley CW, Han C..  (2023)  Synthesis and SAR of a novel Kir6.2/SUR1 channel opener scaffold identified by HTS.,  87  [PMID:36966977] [10.1016/j.bmcl.2023.129256]

84. Sutherland JJ, Yonchev D, Fekete A, Urban L..  (2023)  A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.,  14  (1): [PMID:37468498] [10.1038/s41467-023-40064-9]

Source

Source(12):

• Scientific Literature
• PubChem BioAssays
• Clinical Candidates
• FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• USP Dictionary of USAN and International Drug Names
• DrugMatrix
• AstraZeneca Deposited Data
• CO-ADD antimicrobial screening data
• WHO Anatomical Therapeutic Chemical Classification
• British National Formulary
• SARS-CoV-2 Screening Data 2020-21
• IMI-CARE SARS-CoV-2 Data